Key areas of drug-based therapy in patients with corneoconjunctival xerosis
https://doi.org/10.21518/2079-701X-2015-11-120-125
Abstract
In recent years, dry eye syndrome has attracted an increasing attention from ophthalmologists all over the world. This is largely due to the prevalence of the disease: the average number of people suffering from the disease is 14--15% of the adult population of the developed countries and up to 45% of patients first visiting ophthalmologist [2]. The other reason is severity of the clinical course and outcomes of some clinical types of the dry eye syndrome.
About the Authors
V. V. Brzheskiy
Saint Petersburg State Pediatric Medical University of Ministry of Health of Russia; Mariinsky hospital, St. Petersburg
Russian Federation
Russian Federation
I. V. Kalinina
Saint Petersburg State Pediatric Medical University of Ministry of Health of Russia; Mariinsky hospital, St. Petersburg
Russian Federation
Russian Federation
References
1. Бржеский В.В. Принципы назначения препаратов «искусственной слезы» больным с различными клиническими формами синдрома «сухого глаза». Современные проблемы офтальмологии: Сборник научных статей. СПб.: «Пиастр», 2007. 235-237.
2. Бржеский В.В., Сомов Е.Е. Роговично-конъюнк-тивальный ксероз (диагностика, клиника, лечение). издание 2-е. перераб. и допол. СПб.: «Изд-во Левша. Санкт-Петербург», 2003. 120 с.
3. Еременко А.И., Янченко С.В. Оптимизация терапии возрастной формы синдрома «сухого глаза». Офтальмол. Ведомости, 2010. III, 2: 73-80.
4. Журова С.П, Бржеский В.В., Калинина И.В., Ефимова Е.Л. Лечение язвы роговицы ксеротической этиологии. Клиническая офтальмология, 2010. 11. 2: 49-52.
5. Луцевич Е.Э., Сафонова Т.Н., Лабиди А., Тихомирова Т.Н., Матевосова Э.А. Возможности стимуляции слезопродукции. Современные методы диагностики и лечения заболеваний слезных органов. М., 2005. 201-204.
6. Матевосова Э.А. Возможности стимуляции секреции слезы у больных с гиполакримией при синдроме «сухого» глаза: Автореф. дис.. канд. мед. наук. М., 2009. 24 с.
7. Яни Е.В., Катаргина Л.А., Чеснокова Н.Б. и др. Первый опыт использования препарата Визомитин® в терапии «сухого глаза». Практическая медицина, 2012. 59. 4: 134-137.
8. Янченко С.В. Оптимизация диагностики и терапии возрастной формы синдрома «сухого глаза»: Дисс.. д-ра мед.наук. СПб., 2011. 210 с.
9. Aronowicz JD, Shine WE, Oral D et al. Short term oral minocycline treatment of meibomi-anitis. Brit J. Ophthalmol., 2006. 90: 856-860.
10. Barabino St, Rashid S, Dana MR. Modulation of inflammation and immunity in dry eye disease. Dry eye disease: the clinician's guide to diagnosis and treatment. Ed by: PA. Asbell, M.A. Lemp. New York; Stuttgart: "Thieme", 2006. 95-100.
11. Brown MM, Brown GC, Brown HC et al. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclo-sporine for the treatment of dry eye syndrome. Arch. Ophthalmol., 2009. 127. 2: 146-152.
12. De Paiva CS, Corrales RM, Villarreal AL et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylpred-nisolone and doxycycline. Invest. Ophthalmol. Vis. Sci., 2006. 47: 2847-2856.
13. Dursun D, Kim MS, Solomon A, Pflugfelder SC. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloprotein-ase-9, doxycycline and corticosteroids. Amer. J. Ophthalmol., 2001. 132: 8-13.
14. Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea, 2013. 32, 1: 44-53.
15. Fujishima H, Fuseya M, Ogata M, Murat D. Efficacy of bromfenac sodium ophthalmic solution for treatment of dry eye disease. Asia Pac. J. Ophthalmol., 2015. 4, 1: 9-13.
16. Guillon M, Maissa C, Ho S. Evaluation of the effects on conjunctival tissues of Optive eye-drops over one month usage. Contact Lens Ant. Eye, 2010. 33, Iss.2: 93-99.
17. Kelso GF, Porteous CM, Coulter CV et al. Selective targeting of a redox-active ubiqui-none to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem., 2001. 276: 4588-4596.
18. Li DO, Luo L, Chen Z et al. JNK and ERK MAP kinases mediate induc- tion of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp. Eye Res., 2006. 82: 588-596.
19. Li J, Roubeix Ch, Wang Y et al. Therapeutic efficacy of trehalose eye drops for treatment of murine dry eye induced by an intelligently controlled environmental system. Molec. Vis., 2012. 18: 317-329.
20. Luyckx J, Baudouin Ch. Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology. Clin. Ophthalmol., 2011. 5: 577-581.
21. Matsuo T. Trehalose versus hyaluronan or cellulose in eyedrops for the treatment of dry eye. Jap. J. Ophthalmol., 2004. 48: 321-327.
22. Perry HD, Solomon R, Donnenfeld ED et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch. Ophthalmol., 2008. 126, 8: 1046-1050.
23. Ryan ME, Usman A, Ramamurthy NS et al. Excessive matrix metalloproteinase activity in diabetes: Inhibition by tetracycline analogues with zinc reactivity. Curr. Med. Chem., 2001. 8: 305-316.
24. Skulachev MV,Antonenko YN, Anisimov VN et al. Mitochondrial-targeted plastoquinone deriKva-tives. Effect on senescence and acute age-related pathologies. Curr. Drug Targets, 2011. 12: 800-826.
25. Skulachev VP, Anisimov VN, Antonenko YN et al. An attempt to prevent senescence: a mitochondrial approach. Biochim. Biophys. Acta., 2009. 1787: 437-461.
26. Tsubota K, Kawashima M, Inaba T et al. The antiaging approach for the treatment of dry eye. Cornea, 2012. 31, Suppl.1: 3-8.
27. Versura P, Profazio V, Giuseppe Giannaccare G et al. Discomfort symptoms reduction and ocular surface parameters recovery with Artelac Rebalance treatment in mild-moderate dry eye. Europ. J. Ophthalmol., 2013. 23, 4: 488-495.
28. Wakamatsu TH, Dogru M, Tsubota K. Tearful relations: oxidative stress, inflammation and eye diseases. Arq. Bras. Oftalmol., 2008. 71, Suppl.6: 72-79.
Review
For citations:
Brzheskiy VV, Kalinina IV. Key areas of drug-based therapy in patients with corneoconjunctival xerosis. Meditsinskiy sovet = Medical Council. 2015;(11):120-125. (In Russ.) https://doi.org/10.21518/2079-701X-2015-11-120-125
Views:
415
Email this article 